Trademark Search  /  REINVENTING HOPE

REINVENTING HOPE

○ Dead · Abandoned

U.S. federal trademark · Serial No. 97416720

Mark
REINVENTING HOPE
Status
Abandoned
Serial Number
97416720
Filing Date
May 18, 2022
Class(es)
Class 005, Class 042

Owners

Teon Therapeutics, Inc.
03 · Redwood City, CA, US
Teon Therapeutics, Inc.
03 · Redwood City, CA, US

Goods & Services

Pharmaceutical preparations for treating cancer; pharmaceutical preparations for the treatment or prevention of dermatological, cardiovascular, hematological, circulatory, gastroenterological, digestive, hormonal, rheumatic, immune system, and metabolic diseases and disorders; pharmaceutical preparations for use in immunology, oncology including immuno-oncology, cardiovascular and metabolic diseases; pharmaceutical preparations designed to deliver highly targeted therapeutic modulation to patients suffering from a variety of diseases, including cancer, autoimmune and inflammatory diseases including transplantation and delayed-type hypersensitivity, gastrointestinal diseases, cardiovascular and metabolic diseases, and dermatologic diseases, genitourinary diseases, and orphan diseases; protein therapeutics, namely, pharmaceutical preparations for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, dermatology, urology, gynecology, hepatology; protein therapeutics, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, including cancer and autoimmune disorders, cytokines, interferons, tumor cell targeting and cytolytic agents, tolerogenic and antiallergic factors, growth and differentiation factors, hormones, replacement enzymes, lipid binding proteins, protein factors for manufacturing of adoptive cell therapy products, and tissue repair factors; non-natural protein modifications for use in connection with a variety of therapeutic areas, namely, protein arrays for medical diagnosis purposes; pharmaceutical preparations, namely, synthetic proteins for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, dermatology, urology, gynecology, hepatology

Medical and pharmaceutical research services; pharmaceutical research and development; research and development in pharmacology for the purpose of treating cancer; medical research for use in oncology; pharmaceutical research for treating neuroendocrine tumors; medical research for the treatment or prevention of dermatological, cardiovascular, hematological, circulatory, gastroenterological, digestive, hormonal, rheumatic, immune system, and metabolic diseases and disorders; providing medical and scientific research information in the field of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; pharmaceutical research in the field of protein therapeutics; pharmaceutical research in the fields of immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology, hepatology, laboratory medicine, clinical diagnostics, genetics and phenomics, pathology and forensics, proteomics, veterinary medicine and diagnostics, and basic research tools; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical research using a semi-synthetic organism for use in drug development; pharmaceutical research, namely, research relating to synthetic proteins incorporating one or more non-natural amino acids for improving pharmacological properties; pharmaceutical research, namely, research relating to synthetic proteins for use in connection with a wide variety of therapeutic agents

Thinking of using a similar name?
Search 14 million+ trademarks free and see if your brand conflicts with "REINVENTING HOPE" or anything like it, before you file.
Run a free trademark search →

Source: USPTO federal trademark records. Informational only, not legal advice. Status and details may lag the live USPTO database.